Background: A worldwide variation in policy is seen regarding adjuvant systemic treatment for node negative breast cancer (NNBC). After the first presentations of the 10-year EBCTCG results, a study was carried out in the Netherlands to assess patterns of care and to obtain the views of oncologists as to what constitutes a worthwhile benefit from treatment.
therapy. The majority considered a 10-year survival gain of 6%-10% sufficient to warrant the use of chemotherapy in patients under 50. Surgical oncologists required a larger benefit from treatment than radiotherapists and medical oncologists. The more frequently oncologists treated patients in a research context, the less benefit they required from treatment to make it worthwhile.
Conclusions: Data such as these are valuable input into the process of guideline development, and may help discussion within the profession as to what benefit offsets the burden of treatment.
Key words: adjuvant chemotherapy, attitudes, breast cancer, consensus

Background
A trend is seen towards increasing use of adjuvant chemotherapy in node negative breast cancer (NNBC). Within countries, variation in policy is observed [1] . In the Netherlands, for instance, some hospitals started treating their patients after the first presentations of the ' EBCTCG 10-year results [2] , in 1997. Others still did not treat any patients as late as early 1999. A major factor underlying this variation in policy, is variation in attitudes of oncologists towards treatment. The period of consensus development following the EBCTCG results was highly appropriate to assess these attitudes. More generally, not only for breast cancer, it is of interest to question clinicians as to what benefit makes treatment worthwhile to them. Since new therapeutic options are seldom accompanied by substantial improvements in outcome, discussion is needed as to what constitutes a worthwhile benefit.
The purposes of the study were to assess: 1) the use of adjuvant chemotherapy in NNBC patients under the age of 50; 2) whether the results of the EBCTCG were considered convincing; and 3) the benefit at which clinicians deem chemotherapy worthwhile, and the background characteristics associated with this value.
Methods
All members of the Netherlands Societies for Surgical Oncology and for Medical Oncology, and of the Working Party for Radiotherapy in Breast Cancer received a questionnaire in early 1998, and a reminder after one month. Background characteristics of the clinicians were assessed. Clinicians were asked whether or not adjuvant chemotherapy was given as standard treatment in their hospital to patients under the age of 50. Subsequently, they were asked whether they considered the EBCTCG results sufficient ground to recommend adjuvant chemotherapy to their patients. Finally, the minimally required absolute benefit for considering chemotherapy worthwhile was elicited, in terms of both disease free and overall survival.
Results
Respondent characteristics
Ninety-seven of the two hundred eighty-three surgeons (34%), one hundred eight of the two hundred eighteen medical oncologists (50%), and all twenty-four radiotherapists responded. Thirty percent of the clinicians worked in university hospitals or cancer clinics, and eighty-three percent treated predominantly oncology patients. The majority (81%) treated patients in the context of clinical research. 
Patterns of use
Three respondents indicated that adjuvant chemotherapy was given as standard treatment to all NNBC patients under 50 (Table 1) . Most respondents (64%) stated that adjuvant chemotherapy was given under certain conditions, most commonly related to tumour size and pathology (definitions of 'high risk' varied between oncologists). Thirty-five percent of the respondents indicated that at their hospital NNBC patients under fifty never received adjuvant chemotherapy.
Overview results
One in five oncologists stated that the EBCTCG results are sufficient to recommend chemotherapy (Table 1) . The largest fraction (35%) felt that there is a true effect, but that it is too small, given the side effects. Differences were seen between specialities. Medical oncologists more often assumed the results sufficient than surgical oncologists or radiation oncologists (30% vs. 20% and 4%, respectively, P = 0.02).
Minimally required gain
The majority of clinicians endorsed an absolute benefit of 6%-10%, for both disease free and overall survival (Table 1) . Surgeons required the largest benefit. The proportion requiring a benefit of more than 10% in disease-free survival, e.g., was 58% for surgeons vs. 35% for radiotherapists and 42% for medical oncologists (P = 0.02). Those working in university hospitals or cancer clinics were more likely to accept chemotherapy than others. Three times as many oncologists in nonspecialised centres than in specialised centres required a survival benefit of over 10% (47% vs. 16%, P < 0.001).
The more clinicians treated their patients in the context of clinical research, the smaller benefit they required. A linear association was seen between the proportion of patients treated within trials and the benefit required ( Figure 1) . The association was independent of speciality.
Conclusions
A limitation of our study concerns the low response rate from surgeons. It is possible, though, that joint practices only have returned one form. We had preferred to send an anonymous questionnaire, and thus have no information on the non-responders. Therefore, we cannot speculate on the effect of the response rate on our results.
One third of oncologists stated that NNBC patients under 50 in their hospital never received adjuvant chemotherapy. This contradicts the finding that most clinicians felt that an absolute survival benefit of 6%-10% made chemotherapy worthwhile. At the time of the study the EBCTCG results had been reported at international meetings (the Lancet publication did not appear until half a year later), and the 1998 St. Gallen consensus conference [3] had also recommended the use of chemotherapy in intermediate and high-risk patients. Thus, most clinicians were relatively conservative. As explanation for these treatment patterns we found that 55% of the clinicians believed that the effect seen in the overview was too small or would not translate into practice.
From our data it appears that for most clinicians a benefit of 6%-10% in overall survival makes therapy worthwhile. This figure is important in discussions about policy making, not only for NNBC. It may be contrasted with the much smaller benefit required by patients [4] [5] [6] , since it cannot be expected from the health care system to eliminate all chances of mortality at all costs. Decisions not to provide chemotherapy at small benefits should be taken at a policy level. At the level of the individual patient it may be difficult for the clinician to set a limit.
